In fact, patients with AD exhibited lower levels of cerebral capillary VEGF expression in the hippocampus, superior temporal cortex, and brainstem than controls, whereas treating AD mice models with cells secreting VEGF yielded reductions in memory impairment, tau and amyloid burden48–50. This evidence concerns the gene MAPT and Alzheimer disease.